Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study
Obesity · 2025-04 · 33 (4) · 659-670
DOI: 10.1002/oby.24214 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Obesity, online erschienen am 20.02.2025. Verfasst von Søren Gam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark. Hauptthemen laut MEDLINE: Bone Density, Bone Density Conservation Agents, Imidazoles, Diphosphonates. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Karola Jørgensen Foundation, Steno Diabetes Center Odense, University of Southern Denmark.
Abstract (Originalsprache)
Objective
The aim of this study was to investigate the effects of zoledronic acid for the prevention of bone loss after bariatric surgery.
Methods
In this randomized, double‐blinded study, 59 patients undergoing Roux‐en‐Y gastric bypass or sleeve gastrectomy (mean [SD], age: 48.9 [6.3] years, BMI: 42.3 [5.3], 73% female) were randomly assigned (1:1) to receive either zoledronic acid (5 mg; intervention [INT]) or placebo (control [CON]) preoperatively. The primary endpoint was the change in spine volumetric bone mineral density (vBMD) at 12 months after surgery. Secondary outcomes included changes in hip and femoral neck vBMD and areal BMD.
Results
The estimated mean treatment effects of zoledronic acid on the spine and total hip were 6.8 mg/cm 3 (95% CI 1.9–11.7; p = 0.003) and 5.0 mg/cm 3 (95% CI: 1.4–8.5; p = 0.006), respectively. Bone mass in the spine increased by 2.6% in INT, whereas no changes were observed in CON. Additionally, bone loss in the total hip was prevented in INT compared with CON (vBMD: −0.6% vs. −3.6%; p = 0.006).
Conclusions
Zoledronic acid increases bone mass in the spine and prevents bone loss in the hip region after bariatric surgery compared with placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Esbjerg Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark.
- Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
- Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- Imaging Research Initiative Southwest (IRIS), University Hospital of Southern Denmark, Esbjerg, Denmark.
- Department of Radiology and Nuclear Medicine, University Hospital of Southern Denmark, Esbjerg, Denmark.
- Research Unit of Endocrinology: Bariatrics and Diabetes, University Hospital of Southern Denmark, Esbjerg, Denmark.
ORCID-Profile: Søren Gam
Förderung
- Karola Jørgensen Foundation
- Steno Diabetes Center Odense
- University of Southern Denmark
- Region Syddanmark
- Aase and Ejner Danielsen Foundation
- Fonden til Lægevidenskabens Fremme
- Syddansk Universitet
Zitieren
APA
Gam, S., Lysdahlgaard, S., Gram, B., Kusk, M. W., Hermann, A. P., Juhl, C. B., & Hansen, S. G. (2025). Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study. Obesity, 33(4), 659-670. https://doi.org/10.1002/oby.24214
Vancouver
Gam S, Lysdahlgaard S, Gram B, Kusk MW, Hermann AP, Juhl CB, et al. Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study. Obesity. 2025;33(4):659-670. doi:10.1002/oby.24214
BibTeX
@article{Gam2025,
author = {Gam, Søren and Lysdahlgaard, Simon and Gram, Bibi and Kusk, Martin Weber and Hermann, Anne Pernille and Juhl, Claus Bogh and Hansen, Stinus Gadegaard},
title = {Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study},
journal = {Obesity},
year = {2025},
volume = {33},
number = {4},
pages = {659--670},
doi = {10.1002/oby.24214}
}
EUVIMED